Amneal's Q3 2025: Green Lights, Growth, and Innovation

Amneal Pharmaceuticals reports a successful Q3 2025, with revenues up 12% to $785M and adjusted EBITDA at $160M. Key growth areas include Affordable Medicines (8% to $461M), Specialty (8% to $125M), and AvKARE (24% to $199M). The company is expanding into complex meds and biosimilars, with notable launches and a robust pipeline. Amneal raised full-year guidance, with revenues steady at $3-3.1B, EBITDA at $675-685M, and EPS at $0.75-0.80. The balance sheet is stronger, with net leverage down to 3.7x. Amneal is well-positioned to become the top player in the U.S. affordable medicines market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d0eafc795c1885c0